Get your full text copy in PDF
Chao Zheng, Huang Ding, Linjun Qin, Ali Xiong, Jiulong Wang, Changqing Yin
(Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (mainland))
Med Sci Rev 2018; 5:19-24
Sclerostin, an osteocyte-derived biomarker that regulates bone health via inhibition of the Wnt/β-catenin pathway has been widely researched in adynamic bone disease. In recent years, accumulated evidence demonstrates that there exists a dramatic change in sclerostin levels in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients. Also, more investigations have been performed to assess its potential significance in patients with CKD-MBD, which mainly is a systemic disorder of mineral and bone metabolism. This review summarizes the emerging understanding of sclerostin and its role in different pathological and physiological changes of CKD according to 3 aspects – bone metabolism, vascular calcification, and mineral and electrolyte disorder – to discuss and predict its value in clinical settings.